James Khodabakhsh

This technology allows physicians and researchers to explore the eye for a broad spectrum of diseases, which have previously required long-term clinical evaluation and invasive testing for definitive diagnosis. Amydis has a discovery platform and proprietary know-how that positions it as a first mover and leader in developing ocular tracers for human diseases. The American company was founded in 2013 by Stella Sarraf, who has been the CEO since then.

This technology allows physicians and researchers to explore the eye for a broad spectrum of diseases, which have previously required long-term clinical evaluation and invasive testing for definitive diagnosis. Amydis has a discovery platform and proprietary know-how that positions it as a first mover and leader in developing ocular tracers for human diseases. The American company was founded in 2013 by Stella Sarraf, who has been the CEO since then.

This technology allows physicians and researchers to explore the eye for a broad spectrum of diseases, which have previously required long-term clinical evaluation and invasive testing for definitive diagnosis. Amydis has a discovery platform and proprietary know-how that positions it as a first mover and leader in developing ocular tracers for human diseases. The American company was founded in 2013 by Stella Sarraf, who has been the CEO since then.

This technology allows physicians and researchers to explore the eye for a broad spectrum of diseases, which have previously required long-term clinical evaluation and invasive testing for definitive diagnosis. Amydis has a discovery platform and proprietary know-how that positions it as a first mover and leader in developing ocular tracers for human diseases. The American company was founded in 2013 by Stella Sarraf, who has been the CEO since then.